Here’s how Sanofi separates true innovation from all the hype in digital health

"Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley. Sanofi (NYSE:SNY), for instance, has dove in feet first, striking deals with major tech players like Verily. But weeding out true disruptions from all the noise isn’t easy.
“There’s a lot of hype,” said Rachel Sha, VP of Sanofi’s digital business development & licensing unit. “We work really hard to identify companies that don’t just have nice slides, but actually have early experience and data showing the impact of their technology.” Sanofi sees digital tools as playing a huge role in its business – whether its technology that can help accelerate the development of new therapies or solutions that can be packaged with a drug to boost outcomes for patients and providers...." Lire la suite